RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2023 -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has joined the firm as...
Elitra, whose assets were acquired by Merck in 2004, was an antimicrobial functional genomics company that focused on the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms.
Elitra Phramaceuticals
San Diego, CA
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.